Recent Quotes (30 days)

You have no recent quotes
chg | %

DiagnoCure Inc.  

(Public, TSE:CUR)   Watch this stock  
Find more results for CUR
-0.020 (-14.81%)
Jun 30 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.12 - 0.12
52 week 0.09 - 0.25
Open 0.12
Vol / Avg. 2,000.00/23,882.00
Mkt cap 4.95M
P/E     -
Div/yield     -
EPS -0.04
Shares 43.04M
Beta 0.08
Inst. own     -
Jun 12, 2015
Q2 2015 Diagnocure Inc Earnings Release

Key stats and ratios

Q2 (Apr '15) 2014
Net profit margin -437.62% -367.38%
Operating margin -428.01% -377.64%
EBITD margin - -316.82%
Return on average assets -46.07% -30.37%
Return on average equity - -1213.84%
Employees 10 -
CDP Score - -


4535 boul. Wilfrid-Hamel Ouest,, Bureau 250
+1-418-5276100 (Phone)
+1-418-5270240 (Fax)

Website links


DiagnoCure Inc is a Canada-based biotechnology company, which specializes in the development and commercialization of products relating to the diagnosis of cancer. The Company develops and provides molecular and genomic tests to support effective clinical decisions enabling personalized medicine in oncology. Diagnocure’s main products and projects in oncology are: Progensa PCA3, PrevistageTM GCC and Multigene prostate cancer signature. The Company’s subsidiaries include Catalyst Oncology LP, 9184-6766 Quebec Inc. and 9161-6722 Quebec Inc.

Officers and directors

Yves Fradet M.D. Non-Independent Chairman of the Board, President, Chief Medical Officer
Frederic Boivin Senior Director - Finance and Administration
Vincent R. Zurawski Jr., Ph.D. Non Executive Lead Independent Director
Andrew J. Sheldon Director
Jacques Simoneau Director
Age: 57
Louise Proulx Ph.D. Non-Executive Independent Director